Lenacapavir Approved for HIV Prevention in South Africa
Lenacapavir has been registered by SAHPRA as an innovative HIV prevention injection. Find out more about its rollout in South Africa.
Cipla Medpro faces claims over side effects of antibiotic
Cipla Medpro faces claims that it failed to inform patients properly about Tavaloxx side effects affecting health outcomes.
Twice-Yearly HIV Jab: Activists Call for Lower Prices
Explore the revolutionary Twice-Yearly HIV Jab, a potential game-changer in HIV prevention that raises important affordability questions.
HIV Prevention Strategies with Lenacapavir Injection
In a decision that could fundamentally reshape the fight against HIV, the US Food and Drug Administration (FDA) has given its approval to Gilead Sciences’ lenacapavir, a groundbreaking twice-yearly injection for preventing HIV infection in adults and adolescents. Marketed under the brand name Yeztugo in the US, this innovative drug has been eagerly anticipated by…...
Adcock Ingram: A picture of resilience in a challenging market
Pharmaceutical stalwart Adcock Ingram presents a compelling case for investors seeking resilience amidst potential market turbulence. The group boasts a robust track record, with a mere 3% dip in headline earnings per share (HEPS) during the challenging Covid-impacted year of 2021. It was their worst annual performance in a decade. Since 2015, Adcock has delivered…...